Inactive Instrument

Highlights Albireo Pharma, Inc.

Equities

ALBO

US01345P1066

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Ipsen: acquisition of Albireo Pharma finalized	23-03-03	CF
French Drugmaker Ipsen Concludes Albireo Pharma Takeover	23-03-02	MT
Ipsen Biopharmaceuticals, Inc. completed the acquisition of Albireo Pharma, Inc. from a group of shareholders.	23-02-28	CI
Ipsen Extends Tender Offer for Albireo Pharma as It Awaits US Antitrust Clearance	23-02-22	MT
Ipsen: extension of the deadline for its tender offer for Albireo Pharma	23-02-22	CF
Albireo Pharma, Inc. Announces U.S. Food and Drug Administration Accept Its Supplemental New Drug Application	23-02-14	CI
Albireo Pharma to be Acquired by Ipsen	23-01-09	MT
France's Ipsen Moves to Broaden Rare Disease Portfolio Via $952 Million Purchase of Albireo	23-01-09	MT
AstraZeneca boosts heart, kidney business with $1.8 bln CinCor deal	23-01-09	RE
Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Albireo Pharma, Inc. from a group of shareholders for approximately $910 million.	23-01-08	CI
Albireo Pharma Submits Applications for Second Bylvay Indication in US, Europe	22-12-19	MT
Albireo Pharma, Inc. Submits Bylvay(R) Alagille Syndrome Regulatory Filings to FDA and EMA	22-12-19	CI
Albireo Pharma Swings to Q3 Loss, Revenue Rises; Shares Drop	22-11-08	MT
Albireo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Earnings Flash (ALBO) ALBIREO PHARMA Reports Q3 Revenue $9.8M, vs. Street Est of $9.54M	22-11-08	MT
Albireo Pharma, Inc. Presents New Data at the American Association for the Study of Liver Diseases	22-11-07	CI
Albireo Pharma, Inc. Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia	22-11-02	CI
Albireo Pharma, Inc. to Present Late Breaking Bylvay Data at AASLD 2022	22-11-01	CI
Albireo Pharma, Inc. Presents Data on Greater Efficacy in PFIC with Earlier Bylvay Treatment at NASPGHAN	22-10-13	CI
Albireo Pharma, Inc. Reports Positive Topline Data from Phase 3 Trial of Bylvay® in Alagille Syndrome	22-10-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Albireo Pharma, Inc.

Equities

ALBO

US01345P1066

Highlights

Filters